Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China · Delayed Price · Currency is CNY 10.03
+0.23 (2.35%)
Jun 2, 2026, 3:12 PM CST
Xiangxue Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,595 | 1,839 | 2,273 | 2,166 | 2,930 |
Other Revenue | - | 19.76 | 26.76 | 20.75 | 40.87 |
| 1,595 | 1,859 | 2,299 | 2,187 | 2,971 | |
Revenue Growth (YoY) | -14.16% | -19.16% | 5.13% | -26.38% | -3.30% |
Cost of Revenue | 1,159 | 1,451 | 1,556 | 1,654 | 2,229 |
Gross Profit | 435.94 | 407.61 | 743.33 | 533.38 | 741.4 |
Selling, General & Admin | 436.8 | 522.29 | 583.02 | 602.22 | 659.02 |
Research & Development | 70.95 | 79.39 | 89.76 | 94.79 | 90.6 |
Other Operating Expenses | 4.79 | 7.08 | 12.83 | 10.44 | 13.6 |
Operating Expenses | 512.54 | 641.53 | 693.66 | 708.73 | 763.79 |
Operating Income | -76.6 | -233.92 | 49.67 | -175.35 | -22.39 |
Interest Expense | - | -232.85 | -237.06 | -213.2 | -202.06 |
Interest & Investment Income | - | 2.78 | 1.2 | 51.24 | 41.84 |
Currency Exchange Gain (Loss) | - | -0 | -0 | 0.08 | 0.01 |
Other Non Operating Income (Expenses) | -723.14 | -0.71 | -70.83 | -23.79 | -8.94 |
EBT Excluding Unusual Items | -799.74 | -464.71 | -257.01 | -361.02 | -191.54 |
Impairment of Goodwill | - | - | - | - | -353.87 |
Gain (Loss) on Sale of Investments | -1.61 | -5.36 | -60.01 | -0.01 | 15.64 |
Gain (Loss) on Sale of Assets | 8.92 | 6.99 | 0.09 | 4.97 | 2.34 |
Asset Writedown | -544.41 | -334.92 | -105.38 | -129.64 | -90.7 |
Legal Settlements | - | - | - | - | -16.58 |
Other Unusual Items | - | -44.07 | 33.37 | -26.16 | -1.07 |
Pretax Income | -1,337 | -842.07 | -388.95 | -511.86 | -635.78 |
Income Tax Expense | 33.95 | 19.15 | 12.8 | -7.22 | 22.92 |
Earnings From Continuing Operations | -1,371 | -861.22 | -401.75 | -504.65 | -658.7 |
Minority Interest in Earnings | -21.39 | 2.66 | 12.78 | -25.41 | -29.77 |
Net Income | -1,392 | -858.56 | -388.96 | -530.06 | -688.47 |
Net Income to Common | -1,392 | -858.56 | -388.96 | -530.06 | -688.47 |
Shares Outstanding (Basic) | 660 | 660 | 659 | 663 | 662 |
Shares Outstanding (Diluted) | 660 | 660 | 659 | 663 | 662 |
Shares Change (YoY) | -0.10% | 0.18% | -0.50% | 0.09% | 0.89% |
EPS (Basic) | -2.11 | -1.30 | -0.59 | -0.80 | -1.04 |
EPS (Diluted) | -2.11 | -1.30 | -0.59 | -0.80 | -1.04 |
Free Cash Flow | 118.12 | -17.07 | 207.41 | -139.89 | -305.18 |
Free Cash Flow Per Share | 0.18 | -0.03 | 0.32 | -0.21 | -0.46 |
Gross Margin | 27.32% | 21.93% | 32.33% | 24.39% | 24.96% |
Operating Margin | -4.80% | -12.58% | 2.16% | -8.02% | -0.75% |
Profit Margin | -87.26% | -46.19% | -16.92% | -24.24% | -23.18% |
Free Cash Flow Margin | 7.40% | -0.92% | 9.02% | -6.40% | -10.27% |
EBITDA | 113.65 | -15.7 | 282.2 | 60.29 | 125.02 |
EBITDA Margin | 7.12% | -0.84% | 12.27% | 2.76% | 4.21% |
D&A For EBITDA | 190.25 | 218.22 | 232.53 | 235.64 | 147.41 |
EBIT | -76.6 | -233.92 | 49.67 | -175.35 | -22.39 |
EBIT Margin | -4.80% | -12.58% | 2.16% | -8.02% | -0.75% |
Revenue as Reported | - | 1,859 | 2,299 | 2,187 | 2,971 |
Advertising Expenses | - | 7.78 | 6.33 | 9.46 | 34.1 |